CK Regeon is Drug Discovery in South Korea that focus on bio-pharmaceutical designed business. Founded in 2016. They cover business area such as developer, bio-pharmaceutical, human life, drug development, disease, small molecule, peptide, metabolic disorder, target-specific compound, medical practitioner, obesity, diabete, non-alcoholic steatohepatitis, hair growth, healing.
2016
( 8 years old in 2024 )
Bio-pharmaceutical Designed
-
Yonsei Engineering Research Park Yonsei University Yonsei-ro 50
Suite B134
Seodaemoon-gu, Seoul
South Korea
Private
developerbio-pharmaceuticalhuman lifedrug developmentdiseasesmall moleculepeptidemetabolic disordertarget-specific compoundmedical practitionerobesitydiabetenon-alcoholic steatohepatitishair growthhealing
* We use standard office opening hours in near CK Regeon's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
CK Regeon is Drug Discovery business from South Korea that founded in 2016 (8 years old in 2024), CK Regeon business is focusing on Bio-pharmaceutical Designed.
CK Regeon headquarter office and corporate office address is located in Yonsei Engineering Research Park Yonsei University Yonsei-ro 50 Suite B134 Seodaemoon-gu, Seoul South Korea.
CK Regeon was founded in South Korea.
In 2024, CK Regeon is currently focus on bio-pharmaceutical designed sector.
Above is snippet of Google Trends for "bio-pharmaceutical designed" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with CK Regeon, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
